Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(147 productos)
- Bcr-Abl(103 productos)
- EGFR(572 productos)
- FAK(71 productos)
- FLT(91 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(246 productos)
- PDGFR(126 productos)
- RAAS(87 productos)
- Src(80 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(262 productos)
Mostrar 6 subcategorías más
Se han encontrado 1522 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
pan-HER-IN-1
CAS:<p>Compound C5: Irreversible, oral pan-HER inhibitor with low IC50s for EGFR/HERs; induces apoptosis and has antitumor effects.</p>Fórmula:C19H14BrN5OForma y color:SolidPeso molecular:408.25EGFR/HER2/TS-IN-2
CAS:<p>EGFR/HER2/TS-IN-2: Strong EGFR, HER2 & TS inhibitor; EGFR IC50=0.173μM, HER2 IC50=0.125μM, TS IC50=1.12μM; kills MDA-MB-231 cells (IC50=1.69μM).</p>Fórmula:C26H21N7OS2Forma y color:SolidPeso molecular:511.62BSc5371
CAS:<p>BSc5371: Irreversible FLT3 inhibitor; Kds 0.83-5.8 nM for various FLT3 mutants including wild type.</p>Fórmula:C24H31N5O4SPureza:98%Forma y color:SolidPeso molecular:485.6Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Pureza:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Forma y color:LiquidEsuberaprost Sodium
CAS:<p>Famitinib (SHR1020), an oral drug, inhibits c-kit, VEGFR-2, and PDGFRβ (IC50: 2.3/4.7/6.6 nM) and triggers apoptosis in gastric cancer.</p>Fórmula:C23H27FN4O2Forma y color:SolidPeso molecular:410.48MS 154N
CAS:<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Fórmula:C47H56ClFN8O8Forma y color:SolidPeso molecular:915.45c-ABL-IN-2
CAS:<p>C-ABL-IN-2 is a potent c-Abl protein inhibitor, promising for research in cancer and neurodegenerative diseases like ALS and PD.</p>Fórmula:C21H20N4OForma y color:SolidPeso molecular:344.41BPTQ
CAS:<p>BPTQ: DNA intercalator, halts cancer cell growth by blocking S/G2/M phases.</p>Fórmula:C17H16N4SPureza:98%Forma y color:SolidPeso molecular:308.4JNJ-47117096 hydrochloride
CAS:JNJ-47117096 hydrochloride is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM.Fórmula:C21H23ClN4O2Forma y color:SolidPeso molecular:398.89JAK-2/3-IN-2
CAS:<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Fórmula:C19H19ClN2OSForma y color:SolidPeso molecular:358.89MAX-40279 hemiadipate
CAS:<p>MAX-40279 hemiadipate: Potent FLT3/FGFR inhibitor; potential in AML treatment. (Patent WO2021180032A1)</p>Fórmula:C50H56F2N12O6S2Forma y color:SolidPeso molecular:1023.19Squarunkin A hydrochloride
CAS:<p>Squarunkin A HCl inhibits UNC119-cargo binding, specifically blocks Src kinase activation, IC50=10 nm.</p>Fórmula:C25H33ClF3N5O4Forma y color:SoildPeso molecular:560.02EGFR-IN-67
CAS:<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Fórmula:C18H17N3SForma y color:SolidPeso molecular:307.41TK4g
CAS:<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Fórmula:C19H19N3O4SForma y color:SolidPeso molecular:385.44VEGFR-2/BRAF-IN-2
<p>VEGFR-2/BRAF-IN-2 inhibits VEGFR-2, BRAF V600E, BRAF WT (IC50: 0.111/0.089/0.071 µM); induces G1 arrest and apoptosis.</p>Fórmula:C26H21ClF3N5O3S2Forma y color:SolidPeso molecular:608.05TC-S 7003
CAS:TC-S 7003 (Lck Inhibitor) is a Lck inhibitor with anti-inflammatory activity that inhibits T-cell proliferation and can be used to study arthritis.Fórmula:C31H30N8OPureza:99.74%Forma y color:SolidPeso molecular:530.62EGFR-IN-68
CAS:<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Fórmula:C24H22N2OForma y color:SolidPeso molecular:354.44(E/Z)-AG490
CAS:<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Fórmula:C17H14N2O3Forma y color:SolidPeso molecular:294.3ULK1-IN-2
CAS:<p>ULK1-IN-2, a potent anticancer agent, inhibits ULK1, induces apoptosis, blocks autophagy, and shows high cytotoxicity with an IC50 of 1.94 μM in A549 cells.</p>Fórmula:C19H16BrFN4O6Pureza:99.25% - 99.25%Forma y color:SolidPeso molecular:495.26T338C Src-IN-2
CAS:<p>T338C Src-IN-2: Potent c-Src T338C kinase inhibitor; IC50: 317 nM, T338C/V323A: 57 nM, T338C/V323S: 19 nM.</p>Fórmula:C17H18FN5OPureza:98%Forma y color:SolidPeso molecular:327.36ENMD-1198
CAS:<p>ENMD-119 is a 2-methoxyestradiol analog with antiproliferative and antiangiogenic activity. It is suitable for inhibiting HIF-1α and STAT3 in human HCC cells.</p>Fórmula:C20H25NO2Pureza:98%Forma y color:SolidPeso molecular:311.42AG-183
CAS:<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Fórmula:C13H8N4O3Forma y color:Brown SolidPeso molecular:268.23PD180970
CAS:<p>PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit.</p>Fórmula:C21H15Cl2FN4OPureza:98.67%Forma y color:SolidPeso molecular:429.27Antiproliferative agent-30
CAS:<p>Antiproliferative agent-30 (Compound 8g) demonstrates broad-spectrum antiproliferative activity, with IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM against</p>Fórmula:C24H26N4O4Forma y color:SolidPeso molecular:434.49DB07107
CAS:<p>DB07107 is a potent inhibitor of drug resistant T315I mutant Bcr-Abl tyrosine kinase and a potent Akt1 inhibitor (IC50: 360 nM).</p>Fórmula:C23H22N4OPureza:98%Forma y color:SolidPeso molecular:370.45QL-X-138
CAS:<p>QL-X-138: Dual BTK/MNK inhibitor; covalent to BTK, IC50=9.4 nM; non-covalent to MNK1/2, IC50=107.4/26 nM; dengue virus 2 IC50=3.5 μM; for B-cell malignancies.</p>Fórmula:C25H19N5O2Pureza:98.82% - 99.50%Forma y color:SolidPeso molecular:421.45NSC81111
CAS:<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Fórmula:C19H16O4Forma y color:SolidPeso molecular:308.33GDC-0834 Racemate
CAS:<p>GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitor</p>Fórmula:C33H36N6O3SForma y color:SolidPeso molecular:596.74FLT3-IN-15
CAS:<p>FLT3-IN-15 is an orally active and potent FLT3 inhibitor, capable of acting on FLT3 (IC50: 0.87 nM) and FLT3/D835Y (IC50: 0.32 nM).</p>Fórmula:C22H23ClFN5O2Forma y color:SolidPeso molecular:443.91ARQ 069
CAS:ARQ 069 inhibits FGFR2 phosphorylation concentration-dependently (IC50: 9.7 µM), without affecting β-actin. Preferentially binds inactive FGFR1/2.Fórmula:C18H15N3Pureza:98%Forma y color:SolidPeso molecular:273.33ALK2-IN-5
CAS:<p>ALK2-IN-5, a pyrazolopyrimidine compound, serves as an inhibitor of ALK2 and FGFR, targeting disorders linked with their activity, including cancer [1].</p>Fórmula:C24H32N8O2Forma y color:SolidPeso molecular:464.56ACP-5862
CAS:ACP-5862, active metabolite of Acalabrutinib, is a BTK inhibitor with an IC50 of 5.0 nM.Fórmula:C26H23N7O3Forma y color:SolidPeso molecular:481.51VA5 TG2 inhibitor
CAS:<p>VA5 inhibits transamidase and GTP-binding by locking protein in an open state, disabling GTPase.</p>Fórmula:C31H34N4O8Pureza:98%Forma y color:SolidPeso molecular:590.62TyK2-IN-2
CAS:TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).Fórmula:C16H18N6OPureza:98%Forma y color:SolidPeso molecular:310.35RET-IN-19
CAS:<p>RET-IN-19, a potent RET inhibitor, anticancer: IC50 6.8 nM (RET-wt), 13.51 nM (RET V804M); for NSCLC research.</p>Fórmula:C28H28N6O4SForma y color:SolidPeso molecular:544.62OICR-0547
CAS:<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>Fórmula:C28H29F3N4O4Pureza:98%Forma y color:SolidPeso molecular:542.55SB-633825
CAS:<p>SB-633825 can inhibit cancer cell growth and angiogenesis.</p>Fórmula:C28H25N3O3SPureza:98%Forma y color:SolidPeso molecular:483.58Rac-ZINC4085554
CAS:<p>Compound 1T-0219 (SC) is a blocker of AKT1-FAK interaction reducing the stimulation of FAK phosphorylation in response to extracellular pressure in human SW620</p>Fórmula:C20H19N3O7Pureza:90%Forma y color:SolidPeso molecular:413.38Ilorasertib hydrochloride
CAS:<p>Ilorasertib hydrochloride (ABT-348 hydrochloride) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A (IC50s:</p>Fórmula:C25H22ClFN6O2SPureza:98.45%Forma y color:SolidPeso molecular:525BTK-IN-24
CAS:BTK-IN-24 is a Bruton's tyrosine kinase (BTK) inhibitor with potential anticancer activity, and it can be used in the study of myeloproliferative disorders.Fórmula:C26H19F4N5O2Pureza:99.61%Forma y color:SolidPeso molecular:509.46Syk-IN-1
CAS:Syk-IN-11 is a selective Syk inhibitor.Fórmula:C18H22N8OForma y color:SolidPeso molecular:366.42LBW242
CAS:<p>LBW242: oral 3-mer Smac mimetic, IAP inhibitor, targets multiple myeloma, enhances TRAIL/chemo death in ovarian cancer, active on mutant FLT3 cells.</p>Fórmula:C27H42N4O2Pureza:98%Forma y color:SolidPeso molecular:454.65HSP90-IN-13
CAS:<p>HSP90-IN-13 (5k): potent HSP90 inhibitor, IC50 25.07 nM, targets EGFR/VEGFR-2/Topo-2, blocks MCF-7 G2/M cycle, induces apoptosis.</p>Fórmula:C26H21N5O3SForma y color:SolidPeso molecular:483.54TG 100572
CAS:<p>TG 100572 is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2</p>Fórmula:C26H26ClN5O2Pureza:98%Forma y color:SolidPeso molecular:475.97PD 166326
CAS:<p>PD166326, a pyridopyrimidine inhibitor, targets Src & Abl tyrosine kinases (IC50: 6 nM & 8 nM) and exhibits antileukemic effects.</p>Fórmula:C21H16Cl2N4O2Forma y color:SolidPeso molecular:427.28ZK-261991
CAS:<p>ZK-261991 is an orally active inhibitor of VEGFR tyrosine kinase(IC50 of 5 nM, VEGFR2).</p>Fórmula:C24H25N7O2Pureza:98%Forma y color:SolidPeso molecular:443.5VI 16832
CAS:VI 16832 is a broad-spectrum Type I kinase inhibitor used to quantify relative kinase abundance and study signaling across SILAC-encoded cancer cell lines.Fórmula:C22H25N5O2Pureza:98%Forma y color:SolidPeso molecular:391.47EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Fórmula:C26H33N9O3SPureza:98.52% - 99.79%Forma y color:SolidPeso molecular:551.66EGFR-IN-59
CAS:<p>EGFR-IN-59: EGFR inhibitor, IC50 = 190 nM, induces apoptosis, cytotoxic to A549 cells (IC50 = 8.62 μM) and WI38 cells (IC50 = 52.6 μM). Use: Various cancers.</p>Fórmula:C27H23N5O4SForma y color:SolidPeso molecular:513.57EGFR/HER2/CDK9-IN-2
CAS:<p>EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.</p>Fórmula:C23H20N4O5S2Forma y color:SolidPeso molecular:496.56
